Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

172.00USD
21 May 2019
Change (% chg)

$-0.78 (-0.45%)
Prev Close
$172.78
Open
$174.65
Day's High
$176.00
Day's Low
$171.80
Volume
223,311
Avg. Vol
306,249
52-wk High
$197.30
52-wk Low
$134.38

Latest Key Developments (Source: Significant Developments)

Edwards Lifesciences Q1 Earnings Per Share $1.18
Wednesday, 24 Apr 2019 

April 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $1.32.Q1 EARNINGS PER SHARE $1.18.Q1 SALES $993 MILLION VERSUS REFINITIV IBES ESTIMATE OF $989.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.22 -- REFINITIV IBES DATA.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 TO $4.3 BILLION REMAINS UNCHANGED.RAISED ITS FULL YEAR 2019 ADJUSTED EARNINGS PER SHARE GUIDANCE TO $5.10 TO $5.35.2019 ADJUSTED EPS GUIDANCE RAISED TO $5.10 TO $5.35.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 TO $4.3 BILLION REMAINS UNCHANGED.FOR Q2 2019, COMPANY PROJECTS TOTAL SALES TO BE BETWEEN $1.02 BILLION AND $1.08 BILLION.FOR Q2 2019, COMPANY PROJECTS ADJUSTED EPS OF $1.27 TO $1.37. ADJUSTED EPS OF $1.27 TO $1.37..Q2 EARNINGS PER SHARE VIEW $1.33, REVENUE VIEW $1.04 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $5.21, REVENUE VIEW $4.14 BILLION -- REFINITIV IBES DATA.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 BILLION TO $4.3 BILLION REMAINS UNCHANGED.EDWARDS LIFESCIENCES - FOR QUARTER, REPORTED TAVR SALES OF $598 MILLION, 8 PERCENT GROWTH RATE OVER Q1 LAST YEAR, OR 10 PERCENT ON AN UNDERLYING BASIS.EDWARDS LIFESCIENCES - DURING QUARTER, RECORDED A $24 MILLION CHARGE RELATED TO PREVIOUSLY ANNOUNCED ACQUISITION OF STRATEGIC TRANSCATHETER TECHNOLOGY.  Full Article

Edwards Lifesciences Says CEO's FY18 Compensation Was $10.3 Mln
Thursday, 28 Mar 2019 

March 27 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2018 TOTAL COMPENSATION WAS $10.3 MILLION VERSUS $10.8 MILLION IN FY 2017 - SEC FILING.EDWARDS LIFESCIENCES CORP SAYS ESTIMATE RATIO OF CEO’S TOTAL COMPENSATION FOR 2018 TO MEDIAN OF TOTAL COMPENSATION OF ALL OF EMPLOYEES TO BE 206 TO 1.  Full Article

Edwards Lifesciences Invests $35 Mln In An Exclusive Right To Acquire Corvia Medical Inc
Monday, 11 Mar 2019 

March 11 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES ANNOUNCES STRATEGIC INVESTMENTS.EDWARDS LIFESCIENCES CORP - EDWARDS HAS INVESTED $35 MILLION IN AN EXCLUSIVE RIGHT TO ACQUIRE CORVIA MEDICAL, INC..EDWARDS LIFESCIENCES CORP - EDWARDS HAS ALSO ACQUIRED CERTAIN ASSETS OF MITRALIGN, INC.,.EDWARDS LIFESCIENCES CORP - ADDITIONAL TERMS OF THESE TRANSACTIONS REMAIN CONFIDENTIAL.EDWARDS LIFESCIENCES CORP - ANNOUNCEMENT IS NOT EXPECTED TO IMPACT EDWARDS' 2019 FINANCIAL GUIDANCE..  Full Article

Edwards Comments On U.S. Court Decision
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMMENTS ON U.S. COURT DECISION.COMMENTED TODAY ON A FEDERAL JURY'S DECISIONS IN PATENT LITIGATION BETWEEN EDWARDS AND BOSTON SCIENTIFIC.EDWARDS LIFESCIENCES-DOES NOT EXPECT TO PAY JURY AWARD SINCE U.S. PATENT AND TRADEMARK OFFICE DETERMINED ASSERTED CLAIMS OF '608 PATENT WERE INVALID.  Full Article

Edwards Lifesciences Reports Q2 Earnings Of $1.32/Share
Friday, 27 Jul 2018 

July 26 (Reuters) - Edwards Lifesciences Corp ::QUARTERLY EARNINGS PER SHARE $1.32.QUARTERLY ADJUSTED EARNINGS PER SHARE $1.24.QUARTERLY SALES $944 MILLION, UP 12 PERCENT.QUARTERLY TOTAL ADJUSTED SALES $972 MILLION, UP 10 PERCENT.SAYS 2018 ADJUSTED. EARNINGS PER SHARE OUTLOOK RAISED TO $4.60-$4.75 FROM $4.50-$4.70.SAYS CONFIDENT IN ACHIEVING HIGHER END OF 2018 SALES OUTLOOK RANGE OF $3.5 BILLION-$3.9 BILLION.SEES Q3 TOTAL SALES OF $900 MILLION-$950 MILLION.SEES Q3 ADJUSTED EARNINGS PER SHARE OF $0.93-$1.03.QUARTERLY TRANSCATHETER HEART VALVE THERAPY SALES OF $585 MILLION, UP 20 PERCENT.Q2 EARNINGS PER SHARE VIEW $1.14, REVENUE VIEW $969.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.63, REVENUE VIEW $3.84 BILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $934.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Edwards Lifesciences Says Entered Into Credit Agreement To Establish Multi-Currency Unsecured Revolving Credit Facility - SEC Filing
Tuesday, 1 May 2018 

April 30 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES SAYS ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY - SEC FILING.EDWARDS LIFESCIENCES SAYS NEW AGREEMENT TO REPLACE THE EXISTING $750 MILLION UNSECURED REVOLVING CREDIT FACILITY UNDER THE 2014 CREDIT AGREEMENT.EDWARDS LIFESCIENCES - MAY INCREASE AMOUNT OF REVOLVING CREDIT FACILITY UNDER CREDIT AGREEMENT BY UP TO ADDITIONAL $250 MILLION IN THE AGGREGATE.  Full Article

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
Tuesday, 17 Apr 2018 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES.BOSTON SCIENTIFIC CORP - SUCCESSFULLY OPPOSED EDWARDS LIFESCIENCES' EUROPEAN PATENT EP 2,399,550, RESULTING IN REVOCATION OF PATENT.BOSTON SCIENTIFIC - GERMAN COURT OF APPEAL TO HAVE HEARING IN MAY, JUNE THIS YEAR ABOUT CO'S PATENTS '254, '766 THAT EDWARDS WAS FOUND TO INFRINGE.  Full Article

Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016
Friday, 30 Mar 2018 

March 29 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING.  Full Article

Edwards Lifesciences Corp Acquires Harpoon Medical
Thursday, 7 Dec 2017 

Dec 6 (Reuters) - Edwards Lifesciences Corp ::EDWARDS ACQUIRES HARPOON MEDICAL.EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1.EDWARDS LIFESCIENCES - THERE IS POTENTIAL FOR UP TO $150 MILLION IN MILESTONE PAYMENTS OVER NEXT 10 YEARS AS PART OF DEAL.EDWARDS LIFESCIENCES - JAMES GAMMIE HAD AN EQUITY INTEREST IN HARPOON MEDICAL, AND WILL SERVE AS A CONSULTANT TO EDWARDS LIFESCIENCES.  Full Article

Edwards Lifesciences reports quarterly share of $0.79
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Edwards Lifesciences Corp ::Edwards Lifesciences - Qtrly earnings per share $0.79; Qtrly adjusted earnings per share $0.84; Qtrly sales $821.5 million, up 11.1 percent.Edwards Lifesciences - Qtrly Transcatheter Heart Valve Therapy sales of $481.2 million, up 17.3 percent.Q3 earnings per share view $0.86, revenue view $832.0 million -- Thomson Reuters I/B/E/S.Edwards lifesciences - Reaffirmed FY sales estimate at high end of $3.2 to $3.4 billion range, FY adjusted EPS estimate of $3.65 to $3.85.Edwards lifesciences - "Experienced minimal business impact" from recent natural disasters.FY2017 earnings per share view $3.78, revenue view $3.39 billion -- Thomson Reuters I/B/E/S.  Full Article

Edwards, Medtronic heart valve systems prove worth in low-risk patients: studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.